SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 26.04-0.4%3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: aknahow who wrote (10610)7/6/1999 5:40:00 PM
From: aknahow  Read Replies (2) of 17367
 
Based on input into the blinding and unblinding process I have learned that once data is
unblinded the ability to use information from a look back period which has not been
reached is lost. So if XOMA did look at the data on the 13 th. of July it would lose the
ability to include information from the subjects which had not yet reached the 90 day
look back period, which will be reached for all only on Aug. 13th.

But, even while unblinding sooner rather than later is not risk free for XOMA,
enrollment during the last month was slow and IMO if the drug can't win approval based
on the 10 day and 60 day data for all and the 90 day data for 90% of the subjects then
inclusion of the 90 day data for the remaining 10% is not going to get the drug
approved.

But XOMA will make its' own decisions. It is just not assured that they will look on the
13 th. Just hope some scientist does not make the decision of when to look. <g>
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext